Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli.

The Journal of antimicrobial chemotherapy - 1 Jun 2005

Marcusson Linda L, Olofsson Sara K, Komp Lindgren Patricia, Cars Otto, Hughes Diarmaid

Abstract excerpt

OBJECTIVES: To measure the mutant prevention concentration (MPC) of ciprofloxacin for a set of urinary tract infection (UTI) Escherichia coli isolates with different levels of susceptibility and determine whether MPC can be predicted from MIC. METHODS: MPC was defined as the lowest ciprofloxacin concentration that prevented the growth of resistant colonies when 10(10) bacteria were spread on solid medium and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Ciprofloxacin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Escherichia coli

Share to Mutation

Share to Urinary Tract Infections

Source

Identifiers

PMID: 15860549
DOI: 10.1093/jac/dki136

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli.PMID 15860549Read ↗

Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.Semantic proximity Read ↗

Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.Semantic proximity Read ↗

Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

[Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].Semantic proximity Read ↗

Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.Semantic proximity Read ↗

Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.